Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANFOL feasibility study of mangafodipir with FOLFOX6 in Duke C colorectal cancer
2007-002905-34Phase 2Completed
- Sponsor
- Egetis Therapeutics
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of mangafodipir in colorectal cancer (CRC), sponsored by Egetis Therapeutics. Primary endpoints: Neutropenia and Neurosensory toxicity. Started Oct 2007; status: completed.
02
Drugs
mangafodipir
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2007-002905-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002905-34.